Alain G. Bertoni, MD, MPH
Alain G. Bertoni, M.D., M.P.H., Professor and Chair, Department of Epidemiology and Prevention
Dr. Bertoni is a board certified general internist, Professor and Chair of Epidemiology and Prevention at Wake Forest School of Medicine. A native of New York, NY, his education was at Yale University (B.A., political sciences) and Johns Hopkins (M.D., School of Medicine 1995, M.P.H. School of Public Health 1999). His training was also at Johns Hopkins (1995-1998 residency and 1998-2001 a post-doctoral fellowship. He has been author or co-author of over 100 research publications in the areas of diabetes, cardiovascular disease, and ethnic/racial disparities.
SYNOPSIS OF AREA OF INTEREST: His research interests include the etiology and prevention of diabetes-related complications, especially cardiovascular disease; quality improvement in chronic disease, and ethnic disparities in health and healthcare.
DETAILED AREA OF INTEREST: Dr. Bertoni’s research activities involve field center management, recruitment, and events ascertainment/adjudication for a variety of epidemiologic studies and clinical trials in which diabetes is the major focus or an important secondary focus. These have allowed for investigations into the relationship between diabetes and its cardiovascular complications. Dr. Bertoni is currently a co-investigator in the Multi Ethnic Study of Atherosclerosis (MESA) for which he is the Field Center medical director. He is also co-Principal Investigator in a MESA ancillary study focused on Heart Failure in the 6th exam cycle. He is also a co-investigator in the Atherosclerosis In Communities (ARIC) cohort study, serving on the heart failure committee. Currently his is Principal Investigator of the Jackson Heart Study Diabetes Obesity Working Group, which was established to facilitate and promote analyses of diabetes and obesity in this African American cohort based in Jackson, MS. He has Coordinating Center experience as a co-investigator in the NIDDK-funded Look AHEAD trial of weight loss in type 2 diabetes, for which he served on the study Safety and Economic Evaluation committees. He was initially a co-investigator, and later a PI, in the ACCORD trial of glucose, blood pressure, and lipid control in type 2 diabetes and was responsible for blood pressure data monitoring in 12 southeastern clinics, and served as an adjudicator on the Morbidity and Mortality committee. Finally, he is leading the Lifestyle Intervention for Treatment of Diabetes (LIFT) trial, which is focused on overweight and obese adults with type 2 diabetes in the Forsyth County area. These experiences have led to his collaboration with Regenerative Medicine. There are many potential applications of this field to diabetes, be it replacement therapy aiming to correct the underlying pathophysiology of diabetes, or in ameliorating/ reversing the cardiovascular complications. His expertise with human-subjects research and epidemiology lend itself well to the translation of basic science research to the clinical arena.